Drug Profile


Alternative Names: Mannopentaose phosphate sulfate; Muparfostat sodium; Phosphomannopentaose sulfate; PI-88; PI-88 sodium; PI88-cpd; Sulfated mannopentaose phosphate

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Australian National University
  • Developer Medigen Biotechnology Corporation; Progen Pharmaceuticals; Progen Pharmaceuticals Limited; TBG Diagnostics Limited
  • Class Antineoplastics; Antithrombotics; Mannans; Oligosaccharides
  • Mechanism of Action Fibroblast growth factor inhibitors; Heparanase inhibitors; Heparin cofactor II stimulants; Lipoprotein-associated coagulation inhibitor stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase I/II Solid tumours
  • Discontinued Cardiovascular disorders; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Thrombosis

Most Recent Events

  • 09 Aug 2017 Adverse events and efficacy data from the phase III PATRON trial in Liver cancer released by Medigen Biotechnology
  • 08 Aug 2017 Adverse events data from a phase II trial in Liver cancer released by Medigen Biotechnology
  • 28 Jul 2017 Phase-III development for Liver cancer (Adjuvant therapy) is ongoing in China, Hong Kong, South Korea, and Taiwan (SC) (Medigen Biotechnology website, July 2017) (TBG Diagnostics Limited Annual Report 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top